Loading
A European trial that gives the tablet elacestrant to women whose blood shows hormone-receptor-positive breast cancer returning before scans do, to see whether it delays spread.
TREAT ctDNA (NCT05512364, EORTC) screens patients with ER-positive, HER2-negative breast cancer for ctDNA every six months; those who become ctDNA-positive by the Signatera assay (or another assay approved for diagnosis) without distant metastasis are randomised 1:1 to elacestrant or their current endocrine therapy (tamoxifen, letrozole, anastrozole or exemestane in the registry). Natera and the Menarini Group are collaborators. The primary endpoint is distant metastasis-free survival; primary completion is estimated for November 2032.
Shares Tumour-informed versus tumour-naive ctDNA assays, Signatera, Estrogen receptor (ERα), Minimal / molecular residual disease (MRD).
Shares Anastrozole, Exemestane, Letrozole (and other aromatase inhibitors), Tamoxifen.
Shares Elacestrant, Exemestane, Letrozole (and other aromatase inhibitors), Tamoxifen.
Shares Natera, Tumour-informed versus tumour-naive ctDNA assays, Signatera, Minimal / molecular residual disease (MRD).
Shares Anastrozole, Exemestane, Letrozole (and other aromatase inhibitors), Tamoxifen.
Shares TRAK-ER, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/